Qiagen NV (NASDAQ:QGEN)‘s stock had its “buy” rating restated by stock analysts at DZ Bank AG in a note issued to investors on Monday.

Other equities research analysts have also recently issued reports about the company. Zacks Investment Research cut Qiagen NV from a “hold” rating to a “sell” rating in a research note on Monday, July 25th. Commerzbank AG reaffirmed a “buy” rating on shares of Qiagen NV in a research note on Wednesday, August 31st. Piper Jaffray Cos. reaffirmed a “hold” rating on shares of Qiagen NV in a research note on Thursday, May 26th. HSBC raised Qiagen NV from a “hold” rating to a “buy” rating in a research note on Monday, August 1st. Finally, Jefferies Group reaffirmed a “hold” rating on shares of Qiagen NV in a research note on Thursday, August 4th. Seven research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $25.36.

Analyst Recommendations for Qiagen NV (NASDAQ:QGEN)

Qiagen NV (NASDAQ:QGEN) opened at 26.19 on Monday. The company’s 50-day moving average price is $26.76 and its 200 day moving average price is $23.35. The firm has a market capitalization of $6.13 billion, a price-to-earnings ratio of 52.38 and a beta of 0.90. Qiagen NV has a 12 month low of $19.94 and a 12 month high of $28.04.

Qiagen NV (NASDAQ:QGEN) last posted its earnings results on Thursday, July 28th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. The company earned $334.40 million during the quarter, compared to analysts’ expectations of $326.73 million. Qiagen NV had a return on equity of 9.21% and a net margin of 9.13%. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.26 earnings per share. Analysts predict that Qiagen NV will post $1.09 EPS for the current year.

Hedge funds have recently bought and sold shares of the stock. Franklin Resources Inc. increased its stake in Qiagen NV by 0.5% in the second quarter. Franklin Resources Inc. now owns 26,190,642 shares of the company’s stock valued at $566,914,000 after buying an additional 125,887 shares during the last quarter. Manning & Napier Advisors LLC increased its stake in Qiagen NV by 31.7% in the second quarter. Manning & Napier Advisors LLC now owns 6,111,364 shares of the company’s stock valued at $133,287,000 after buying an additional 1,470,315 shares during the last quarter. Vanguard Group Inc. increased its stake in Qiagen NV by 0.6% in the second quarter. Vanguard Group Inc. now owns 5,287,123 shares of the company’s stock valued at $115,312,000 after buying an additional 29,628 shares during the last quarter. BlackRock Fund Advisors increased its stake in Qiagen NV by 6.7% in the first quarter. BlackRock Fund Advisors now owns 5,062,893 shares of the company’s stock valued at $113,105,000 after buying an additional 318,905 shares during the last quarter. Finally, Harris Associates L P increased its stake in Qiagen NV by 62.6% in the second quarter. Harris Associates L P now owns 3,331,940 shares of the company’s stock valued at $72,670,000 after buying an additional 1,282,240 shares during the last quarter. 58.76% of the stock is owned by institutional investors and hedge funds.

About Qiagen NV

QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.

5 Day Chart for NASDAQ:QGEN

Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.